Isolated Growth Hormone Deficiency (IGHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
_page-0001.jpg)
Isolated Growth Hormone Deficiency (IGHD) leads to childhood growth failure due to inadequate growth hormone (GH) action. IGHD can be caused by different mutations in genes and inherited differently. Most IGHD cases are sporadic and caused by hypothalamic or pituitary insults. Symptoms of IGHD vary in type and severity among affected individuals and include anterior hypopituitarism, delayed skeletal maturation, short stature, frequent infections in type III, delayed eruption of teeth, poor growth of nails, and increased cholesterol and LDL levels in the blood. IGHD type 1 is further classified into sub-types 1a and b, with IGHD type 1a being the most severe. IGHD type 2 is inherited in an autosomal dominant pattern and is often considered the most common form of IGHD, excluding idiopathic GHD. IGHD type 3 is an X-linked recessive disorder with a highly variable phenotype. IGHD type IA is caused by GH1 gene mutations and is inherited in an autosomal recessive manner. IGHD type IB can be caused by GH1 or GHRHR gene mutations and inherited in an autosomal recessive manner. IGHD type II is caused by mutations in the GH1 gene and can be inherited in an autosomal dominant manner. IGHD type III is caused by BTK gene mutations and is inherited in an X-linked recessive pattern.
- The incidence of IGHD is
estimated to be 1 per 10,000 live births.
Thelansis’s “Isolated Growth Hormone
Deficiency (IGHD) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2022 To 2032" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Isolated
Growth Hormone Deficiency (IGHD) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Isolated Growth Hormone Deficiency (IGHD) across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Isolated Growth Hormone Deficiency
(IGHD) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment